Olga Frankfurt, MD
The year 2017 saw 4 regulatory approvals in the field of acute myeloid leukemia (AML) that have made significant improvements in patient outcomes.
on Hematologic Malignancies, Frankfurt, an associate professor of medicine at the Feinberg School of Medicine, Northwestern University, discussed advances in the field of AML and challenges that lie ahead.
OncLive: We have seen much progress in the field of AML this past year. Can you highlight some of the advancements?
There have been 4 drugs that have received FDA approval, which includes midostaurin, a FLT3
-targeted therapy given in combination with chemotherapy. This is obviously for FLT3
-expressed patients who express FLT3
... to read the full story